Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01545518
Other study ID # IRB00052646
Secondary ID BT11-000312
Status Terminated
Phase Phase 2
First received November 30, 2011
Last updated August 21, 2014
Start date November 2011
Est. completion date August 2013

Study information

Verified date August 2014
Source Emory University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients. This study consists of a single blood sample, which will be tested for possible immune abnormalities. If enough patients are found who show immune abnormalities, those patients who are still having uncontrolled seizures will be invited to participate in a study of immune treatment with a compound called intravenous immunoglobulin (IVIG).

The study hypothesis is that a significant proportion of the young-onset, refractory, image-negative, partial-onset epilepsy population have an underlying autoimmune disorder, and many of these patients will respond to immune therapies, including IVIG.

At present, the importance of immune abnormalities in causing epilepsy, and the proper treatment when they are found, are both poorly understood. The investigators hope that this study will help us understand the cause of some cases that are difficult to treat.


Description:

The study is divided into two phases:

Phase I: The investigators will screen for evidence of neuronal nuclear, cytoplasmic, and cell surface autoantibodies in our population of new onset refractory, imaging-negative young adult epilepsy patients. This part of the study involves obtaining a single blood sample, equal to about 2 teaspoons.

Phase 2: If a sufficient number of cases are identified, a double-blind crossover study of IVIG treatment will be performed in these patients.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date August 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Diagnosis of uncontrolled epilepsy with at least two seizures a month for three consecutive months.

- Age 18 to 50.

- Clinical semiology or electroencephalogram (EEG) consistent with partial onset epilepsy.

- Refractory to an adequate trial of two or more main-line anti-epileptic drugs.

- Ability to keep a seizure diary.

- Normal brain magnetic resonance imaging (MRI) - 3 Tesla, seizure protocol; with the exception of hippocampal sclerosis

Exclusion Criteria:

- History of severe prematurity or neonatal distress, febrile seizures, moderate or sever traumatic brain injury, stroke, brain tumor, meningitis, encephalitis, neurocutaneous syndromes, or intracranial metal objects.

- Evidence of psychogenic epilepsy.

- History of convulsive status epilepticus.

- History of primary generalized epilepsy in a first degree relative.

- Known serious medical illness.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
IVIG
IVIG 2 mg/kg in two divided doses with placebo crossover

Locations

Country Name City State
United States Grady Memorial Hospital Atlanta Georgia
United States The Emory Clinic, Inc. Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University Baxter Healthcare Corporation

Country where clinical trial is conducted

United States, 

References & Publications (14)

Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997 Jun;120 ( Pt 6):923-8. — View Citation

Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001 Jun;124(Pt 6):1138-48. — View Citation

Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123 ( Pt 7):1481-94. — View Citation

Jacobs DA, Fung KM, Cook NM, Schalepfer WW, Goldberg HI, Stecker MM. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci. 2003 Sep 15;213(1-2):77-82. — View Citation

Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003 Nov;78(11):1363-8. — View Citation

Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998 Mar;50(3):652-7. — View Citation

Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A. Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia. 2007 Sep;9(9):707-15. — View Citation

McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ. Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol. 2009 Feb;66(2):268-71. doi: 10.1001/archneurol.2008.556. Erratum in: Arch Neurol. 2011 Mar;68(3):371. Britton, Jeffrey A [corrected to Britton, Jeffrey W]. — View Citation

Nahab F, Heller A, Laroche SM. Focal cortical resection for complex partial status epilepticus due to a paraneoplastic encephalitis. Neurologist. 2008 Jan;14(1):56-9. doi: 10.1097/NRL.0b013e3181578952. — View Citation

Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov;56(5):715-9. — View Citation

Porta-Etessam J, Ruiz-Morales J, Millan JM, Ramos A, Martínez-Salio A, Berbel-García A. Epilepsia partialis continua and frontal features as a debut of anti-Hu paraneoplastic encephalomyelitis with focal frontal encephalitis. Eur J Neurol. 2001 Jul;8(4):359-60. — View Citation

Rudzinski LA, Pittock SJ, McKeon A, Lennon VA, Britton JW. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res. 2011 Aug;95(3):255-62. doi: 10.1016/j.eplepsyres.2011.04.006. Epub 2011 May 12. — View Citation

Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999 Feb;45(2):255-8. — View Citation

Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004 Apr 13;62(7):1177-82. — View Citation

* Note: There are 14 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Immune Abnormalities neuronal nuclear, cytoplasmic, and cell surface autoantibodies Screening visit No
See also
  Status Clinical Trial Phase
Recruiting NCT01450423 - Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Phase 2
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Recruiting NCT01762215 - Policy on Optimal Epilepsy Management N/A
Completed NCT01941706 - Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT N/A
Completed NCT00179426 - Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy N/A
Completed NCT00433667 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT00425282 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Withdrawn NCT04377425 - COVID-19 Prevalence and Cognitive Deficits in Neurological Patients
Completed NCT03480555 - Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients N/A
Completed NCT03513757 - Dexmedetomidine and Propofol for Pediatric MRI Sedation Phase 4
Not yet recruiting NCT04291716 - Study to Validate Novel Seizure-Detection Algorithm N/A
Recruiting NCT06265103 - Epilepsy Learning Healthcare System (ELHS)
Recruiting NCT03484039 - Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy N/A
Active, not recruiting NCT01978470 - External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy N/A
Completed NCT00179517 - Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT03233399 - Modulating Movement Intention Via Cortical Stimulation N/A
Completed NCT04439656 - Detecting Absence Seizures Using Eye Tracking
Withdrawn NCT04102254 - Thalamic Stimulation for Epilepsy Study N/A